ZA201500102B - Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides - Google Patents

Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides

Info

Publication number
ZA201500102B
ZA201500102B ZA2015/00102A ZA201500102A ZA201500102B ZA 201500102 B ZA201500102 B ZA 201500102B ZA 2015/00102 A ZA2015/00102 A ZA 2015/00102A ZA 201500102 A ZA201500102 A ZA 201500102A ZA 201500102 B ZA201500102 B ZA 201500102B
Authority
ZA
South Africa
Prior art keywords
polynucleotides
polypeptides encoded
immunogenic polypeptides
regimens involving
boosting regimens
Prior art date
Application number
ZA2015/00102A
Other languages
English (en)
Inventor
Ricardo Cortese
Alessandra Vitelli
Alfredo Nicosia
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of ZA201500102B publication Critical patent/ZA201500102B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2015/00102A 2012-07-05 2015-01-07 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides ZA201500102B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/063196 WO2014005643A1 (en) 2012-07-05 2012-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
PCT/EP2013/064286 WO2014006191A1 (en) 2012-07-05 2013-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides

Publications (1)

Publication Number Publication Date
ZA201500102B true ZA201500102B (en) 2017-09-27

Family

ID=48746554

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00102A ZA201500102B (en) 2012-07-05 2015-01-07 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides

Country Status (19)

Country Link
US (3) US20150209420A1 (enExample)
JP (1) JP6244358B2 (enExample)
KR (1) KR20150038010A (enExample)
CN (1) CN104780937A (enExample)
AU (1) AU2013285398A1 (enExample)
BR (1) BR112014033077A2 (enExample)
CA (1) CA2878367A1 (enExample)
DK (1) DK2869841T3 (enExample)
EA (1) EA201492230A1 (enExample)
ES (1) ES2895070T3 (enExample)
HU (1) HUE056675T2 (enExample)
IL (1) IL236414A0 (enExample)
IN (1) IN2014KN03063A (enExample)
LT (1) LT2869841T (enExample)
MX (1) MX365391B (enExample)
PT (1) PT2869841T (enExample)
SG (1) SG11201408746XA (enExample)
WO (2) WO2014005643A1 (enExample)
ZA (1) ZA201500102B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
US11571472B2 (en) * 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
FI3656395T3 (fi) 2014-09-03 2024-02-05 Bavarian Nordic As Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan
JP2017527564A (ja) 2014-09-03 2017-09-21 バヴァリアン ノルディック エー/エス 免疫応答の増進を目的とする方法及び組成物
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP6893177B2 (ja) 2015-05-15 2021-06-23 キュアバック アーゲー 少なくとも1つのmRNAコンストラクトの投与を含むプライムブーストレジメン(PRIME−BOOST REGIMENS)
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsv fポリペプチド
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
MX2018013340A (es) * 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
SG11201908999QA (en) 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Rsv感染に対する防御免疫を誘導するための方法及び組成物
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
CA3076026C (en) * 2017-10-25 2024-10-01 Nouscom Ag EUKARYOTIC CELL LINE
WO2019094396A1 (en) * 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN113164583A (zh) 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511845B1 (en) * 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
SI2163260T1 (sl) 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
EP2001516A4 (en) * 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008085502A2 (en) * 2007-01-05 2008-07-17 Inseron, Inc. A green fluorescent protein optimized for expression with self-cleaving polypeptides
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
US7863425B2 (en) * 2007-09-26 2011-01-04 Cornell University Compositions and methods for inhibiting Yersinia pestis infection
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
CA2749325C (en) 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
AU2010250780A1 (en) * 2009-05-18 2012-01-12 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA)
US9095546B2 (en) * 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
US9125870B2 (en) * 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV

Also Published As

Publication number Publication date
LT2869841T (lt) 2021-11-25
SG11201408746XA (en) 2015-01-29
JP2015526403A (ja) 2015-09-10
WO2014006191A1 (en) 2014-01-09
MX365391B (es) 2019-05-31
IN2014KN03063A (enExample) 2015-05-08
HUE056675T2 (hu) 2022-02-28
MX2014016119A (es) 2015-09-23
AU2013285398A1 (en) 2015-02-05
ES2895070T3 (es) 2022-02-17
EA201492230A1 (ru) 2015-06-30
US20240091338A1 (en) 2024-03-21
CN104780937A (zh) 2015-07-15
IL236414A0 (en) 2015-02-26
WO2014005643A1 (en) 2014-01-09
CA2878367A1 (en) 2014-01-09
US20180256704A1 (en) 2018-09-13
BR112014033077A2 (pt) 2017-08-01
US20150209420A1 (en) 2015-07-30
DK2869841T3 (da) 2021-10-25
JP6244358B2 (ja) 2017-12-06
KR20150038010A (ko) 2015-04-08
PT2869841T (pt) 2021-10-28

Similar Documents

Publication Publication Date Title
IL236414A0 (en) New primary induction regimens involving polynucleotide-encoded immunogenic polypeptides
IL291571A (en) cx3cr1 binding polypeptides
EP2834259A4 (en) MODIFIED POLYNUCLEOTIDES
SG11201503741UA (en) Two-dimensional code
LT2928489T (lt) Imunogeninė kompozicija
GB201220474D0 (en) Polypeptides
EP2809349A4 (en) IMMUNOGENIC COMPOSITION
IL238079A0 (en) Immunogenic preparation
GB201223342D0 (en) Immunogenic composition
SG11201503742XA (en) Two-dimensional code
EP2848291A4 (en) GYRO
SG10201702696PA (en) Immunogenic compositions
DK2941162T3 (en) Formeapparat til formet gulv
GB201218660D0 (en) Immunogenic composition
ZA201501562B (en) Treatment regimens
PL2869841T3 (pl) Nowe schematy prime-boost wykorzystujące polipeptydy immunogenne kodowane przez polinukleotydy
GB201210900D0 (en) Movable platforms
TWM433222U (en) Multifunctional hair-decoration swimming cap
GB201219944D0 (en) Water-powered motor
GB201213753D0 (en) Angle
GB201202102D0 (en) Indu-green energy bio-sustainable project
GB201213339D0 (en) Lev insided matt
GB201219337D0 (en) Garrods movement
AU347499S (en) Top
AU347497S (en) Top